Euro Ewing Consortium
Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases.
The Euro Ewing Consortium is a coalition of clinical study groups bringing together the most active clinicians and scientists in Europe dedicated to improving survival from ES. The EU-funded project supported an integrated programme of investigator-driven, inclusive clinical trials that were rigorously designed, conducted, analysed and reported, and underpinned by complementary embedded translational research. Through collaborative working, the EEC provided ES patients with greater access to clinical trials, allowed efficient acquisition of knowledge and delivered clinically meaningful results that will contribute to improved survival from ES.